cardiovascular disease

Showing 15 posts of 20 posts found.

Amarin’s Vazkepa accepted by SMC for patients with cardiovascular disease

August 8, 2023
Research and Development Cardiology, Vazkepa, cardiovascular disease, pharmaceutical

On 7 August 2023, the Scottish Medicines Consortium (SMC) announced that they had accepted Amarin’s treatment for people with cardiovascular …


Eli Lilly’s Trulicity approved in US to reduce cardiovascular events in type 2 diabetes patients

February 24, 2020
Sales and Marketing Eli Lilly, Trulicity, cardiovascular disease, pharma

Eli Lilly’s Trulicity (duraglutide) has been awarded marketing authorisation from the FDA as a therapy to reduce major adverse cardiovascular …


Novo’s semaglutide injection and tablets get expanded FDA approval for type 2 diabetes with established CVD

January 17, 2020
Medical Communications, Sales and Marketing FDA, Novo Nordisk, Ozempic, cardiovascular disease, diabetes, pharma

Novo Nordisk has seen label expansions approved from the FDA for both its glucagon-like peptide-1 (GLP-1) analogue injection Ozempic (once-weekly …


AstraZeneca’s Farxiga meets Phase 3 primary endpoint in heart failure

August 20, 2019
Manufacturing and Production, Sales and Marketing AstraZeneca, cardiovascular disease, farxiga

New Phase 3 data has been unveiled for AstraZeneca’s Farxiga (dapagliflozin), confirming that the SGLT2 inhibitor met its primary composite …

Bayer’s Xarelto combo greenlighted by NICE for reducing CV events in artery disease

August 1, 2019
Sales and Marketing NHS, NICE, UK, Xarelto, cardiovascular disease, pharma

NICE has awarded final appraisal recommendation to Bayer’s Xarelto (rivaroxaban) at a dosage of 2.5mg twice daily in combination with …


Lilly and Boehringer’s Trajenta matches glimepiride in delaying cardiovascular events in type 2 diabetes patients

February 15, 2019
Medical Communications, Research and Development Boehringer, Eli Lilly, cardiovascular disease, pharma, type 2 diabetes

Boehringer Ingelheim and Eli Lilly’s Trajenta (linagliptin) met its primary endpoint in a recent trial, it has emerged, proving itself …


China’s NMPA approves Amgen’s Repatha to reduce cardiovascular event risk

January 25, 2019
Medical Communications, Sales and Marketing Amgen, China, Repatha, cardiovascular disease, pharma, stroke

Amgen has announced that its proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor Repatha (evolocumab) has secured approval by China’s drug …


Europe expands approved indication of Amgen’s Repatha in cardiovascular disease

May 17, 2018
Sales and Marketing Amgen, Repatha, cardiovascular disease, pharma

Amgen has revealed that its PCSK9 inhibitor Repatha (evolocumab) has received approval from the European Commission in a new indication: …


Pfizer taps real world evidence for CVD in new partnership

February 14, 2018
Research and Development BC Platforms, Pfizer, biotech, cardiovascular disease, drugs, pharma, pharmaceutical

BC Platforms, a company that focuses on genomic data managements and analysis, has announced that it has partnered with Pfizer …


Where will the next cardiovascular breakthrough come from?

August 17, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing British Heart Foundation, cardiovascular disease, heart, heart disease, pharma, pharmaceutical

British Heart Foundation’s Jennifer Mitchell, Research Communications Officer, explains the work they are doing to find the next breakthrough treatment …


Cardiovascular disease expected to place $1 trillion cost burden on US

February 20, 2017
Medical Communications, Sales and Marketing cardiovascular disease

A study conducted by RTI International, a non-profit research institute, has warned that the US could have to balance over …


Heart disease drug development is falling

August 30, 2016
Manufacturing and Production, Research and Development cardiovascular disease, heart disease, research and development

The number of drugs currently in development to combat heart disease has fallen in the last 20 years, it has …

NICE recommends Sanofi, Amgen cholesterol drugs

May 6, 2016
Medical Communications, Sales and Marketing Amgen, Draft Guidance, NHS, NICE, Repatha, Sanofi, cardiovascular disease, cholesterol, final draft guidance, high cholesterol, praluent, recommendation, treatment

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending two new drugs for the …

Latest content